ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

This income gap makes it harder for families to meet essential expenses, sometimes falling below a minimum acceptable income ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on CRSP stock, giving a Buy rating on November 6. Salim Syed’s rating is based on a combination of encouraging developments ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has been given an average recommendation of “Hold” by the nineteen brokerages that are covering the company, Marketbeat Ratings reports. Two ...

Evercore ISI analyst Liisa Bayko maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target ...

CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.

Barclays lowered the firm’s price target on Crispr Therapeutics (CRSP) to $55 from $59 and keeps an Equal Weight rating on ...

Check the time stamp on this data. Updated AI-Generated Signals for Crispr Therapeutics Ag (CRSP) available here: CRSP.

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands ...